Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.43 |
| ▸ | NPC1 | O15118 | 6/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL419949 | 0.73 | NR3C2 (0.37) | NPC1KMT2AALDH1A1MEN1MAPT | |
| SCHEMBL1962212 | 0.72 | FAAH (0.54) | RAB9ANPC1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL21995039 | 0.71 | KDM1A (0.34) | — | |
| SCHEMBL3258353 | 0.71 | TRPV1 (0.60) | RAB9ANPC1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL4982044 | 0.70 | SMN1; SMN2 (0.39) | RAB9ANPC1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL21994290 | 0.70 | KDM1A (0.37) | — | |
| SCHEMBL16585513 | 0.70 | TRPV1 (0.59) | RAB9ANPC1ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL17620813 | 0.70 | FAAH (0.55) | — | |
| SCHEMBL9627157 | 0.70 | TRPV1 (0.51) | RAB9ANPC1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL16913895 | 0.68 | RAB9A (0.53) | RAB9ANPC1KMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550737-B2 | TNF -α modulating benzimidazoles | UCB BIOPHARMA SPRL (BE) | 2017-01-24 | — | — | US | disclosed |
| US-9475820-B2 | Substituted imidazo[1,2-a]pyrazines as TNF activity modulators | UCB BIOPHARMA SPRL (BE) | 2016-10-25 | — | — | US | disclosed |
| US-20150191482-A1 | Imidazopyrazine Derivatives as Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2015-07-09 | — | — | US | disclosed |
| US-20150152065-A1 | TNF -Alpha Modulating Benzimidazoles | UCB BIOPHARMA SPRL (BE) | 2015-06-04 | — | — | US | disclosed |
| EP-2872511-A1 | IMIDAZOPYRAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2015-05-20 | — | — | EP | disclosed |
| EP-2858983-A1 | TNF -ALPHA MODULATING BENZIMIDAZOLES | UCB Biopharma SPRL (BE) | 2015-04-15 | — | — | EP | disclosed |
| WO-2014009296-A1 | IMIDAZOPYRAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB PHARMA S.A. (BE) | 2014-01-16 | — | — | WO | disclosed |
| WO-2013186229-A1 | TNF -ALPHA MODULATING BENZIMIDAZOLES | UCB PHARMA S.A. (BE) | 2013-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152065-A1 | TNF -Alpha Modulating Benzimidazoles | TNF, TNFRSF1A, NFKBIA | RAB9A 1951/4885NPC1 3216/4885KMT2A 3732/4885 |
| US-20150191482-A1 | Imidazopyrazine Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, NFKBIA | RAB9A 1510/4885NPC1 3765/4885KMT2A 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.